Parallel Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Parallel Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6	Closed	-$146	–	3400
2024 Q2	$146	Hold	6	–	–	﹤0.01%	3224
2024 Q1	$203	Hold	6	–	–	﹤0.01%	3150
2023 Q4	$189	Buy	+6	New	+$143	﹤0.01%	3176
2022 Q4	–	Sell	-17	Closed	-$296	–	3356
2022 Q3	$0	Hold	17	–	–	﹤0.01%	3126
2022 Q2	$0	Hold	17	–	–	﹤0.01%	2975
2022 Q1	$0	Sell	17 -58	-77%	-$1.48K	﹤0.01%	2953
2021 Q4	$3K	Buy	75 +47	+168%	+$1.92K	﹤0.01%	2546
2021 Q3	$1K	Buy	28 +8	+40%	+$358	﹤0.01%	2796
2021 Q2	$1K	Hold	20	–	–	﹤0.01%	2678
2021 Q1	$1K	Buy	+20	New	+$1.19K	﹤0.01%	2573

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors's ARCT Position: Q3 2024 in Review

Parallel Advisors sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 6 shares — an estimated $146 sold.

Parallel Advisors first reported a position in ARCT in Q1 2021 and held it in 10 quarters. The position peaked at $3K in Q4 2021. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

Parallel Advisors reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
Parallel Advisors sold 6 Arcturus Therapeutics shares in Q3 2024, an estimated $146.
Parallel Advisors first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 10 quarters.
Parallel Advisors's Arcturus Therapeutics position peaked at $3K in Q4 2021.
164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on Parallel Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.